Tetanus secondary prevention

Jump to navigation Jump to search

Tetanus Microchapters


Patient Information


Historical Perspective




Differentiating Tetanus from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings


CT scan



Other Imaging Studies

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Tetanus secondary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Tetanus secondary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Tetanus secondary prevention

CDC on Tetanus secondary prevention

Tetanus secondary prevention in the news

Blogs on Tetanus secondary prevention

Directions to Hospitals Treating Tetanus

Risk calculators and risk factors for Tetanus secondary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.


Tetanus vaccine can prevent tetanus for approximately 10 years. Post-exposure care is indicated in people who do not know exactly when their last tetanus booster was and who did not complete their primary set of vaccinations. These patients will typically receive passive immunity with tetanus immune globulin (TIG).

Secondary Prevention

Currently, there is a large number of people protected by the Tetanus vaccine which can prevent Tetanus for approximately 10 years. The people that would need specific post-exposure care are those who do not know exactly when their last Tetanus booster was. Post-exposure care may also be indicated in people who did not complete their primary prevention set of vaccinations. These patients will typically receive passive immunity with tetanus immune globulin (TIG). In a situation that would involve a large radius of exposure, the TIG will be reserved for the people who are least likely to have had a primary vaccination series. This includes people older than 60 and immigrants from regions other than North America and Europe. The TIG prophylactic dose that is recommended currently for wounds is 250 units administered intramuscularly (IM) for adult and pediatric patients. In circumstances in which passive protection is clearly indicated but TIG is unavailable, intravenous immune globulin may be substituted for TIG.


Template:WH Template:WS